Next Article in Journal
Structure Enhancement Relationship of Chemical Penetration Enhancers in Drug Transport across the Stratum Corneum
Next Article in Special Issue
In Situ Focused Beam Reflectance Measurement (FBRM), Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Characterization of the Polymorphic Transformation of Carbamazepine
Previous Article in Journal
Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles
Previous Article in Special Issue
Development and Validation of a Microbiological Agar Assay for Determination of Orbifloxacin in Pharmaceutical Preparations
Open AccessArticle

Recrystallization of Commercial Carbamazepine Samples—A Strategy to Control Dissolution Variability

Industrial Pharmacy Lab, University of Basel, Mülhauserstrasse 51, Basel 4056, Switzerland
Author to whom correspondence should be addressed.
Pharmaceutics 2012, 4(1), 58-70;
Received: 5 December 2011 / Revised: 9 January 2012 / Accepted: 10 January 2012 / Published: 13 January 2012
(This article belongs to the Special Issue Solid Dosage Forms)
Physical properties of commercial carbamazepine (CBZ) samples can significantly influence drug release and thereby jeopardize bioequivalence of the final dosage form. The aim of this study was to reduce variability in commercial CBZ samples by recrystallization. CBZ samples of four different suppliers were recrystallized in ethanol solution containing 1% polyvinylpyrrolidone (PVP). CBZ samples were analyzed by disk intrinsic dissolution rate (DIDR), X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Recrystallized CBZ samples showed strongly reduced variability in DIDR compared to the untreated CBZ samples. Moreover, transformation process to CBZ dihydrate was inhibited; no dihydrate crystals were visible on compact surfaces after 8 h intrinsic dissolution measurement. Recrystallized CBZ samples showed no change in polymorphic form, however, particle size and shape was inhomogenous. In binary mixtures with microcrystalline cellulose, recrystallized CBZ samples again showed difference in drug release. This difference was associated with the inhomogenous particle size in the recrystallized CBZ samples. The results show that a controlled grinding step is required after recrystallization. We suggest the recrystallization in presence of 1% PVP followed by a controlled grinding step as a strategy to reduce dissolution variability in commercial CBZ samples. View Full-Text
Keywords: polyvinylpyrrolidone; polymer; intrinsic dissolution; polymorphism; transformation; morphology polyvinylpyrrolidone; polymer; intrinsic dissolution; polymorphism; transformation; morphology
Show Figures

Figure 1

MDPI and ACS Style

Flicker, F.; Eberle, V.A.; Betz, G. Recrystallization of Commercial Carbamazepine Samples—A Strategy to Control Dissolution Variability. Pharmaceutics 2012, 4, 58-70.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop